SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (4507)4/1/1998 2:09:00 AM
From: Vector1  Read Replies (1) of 9719
 
Biowa,
Welcome back. The genomics revolution will forever change the way drugs are designed and pursued. In the past there was a dearth of targets and a dearth promising compounds. Functional genomics and the understanding of pathways is will greatly expand the number of targets. Combinatorial chemistry and high throughput screening will massively increase the number of promising compounds. The key in the future will be deciding which among many promising compounds is the one to run through expensive clinicals. This is where pharmacogenomics will play a huge role allowing pharma and biotechs to run clinical trials on patients who are genetically prescreened to make sure that the drugs mechanism of action will be both efficatious and safe for those patients. Because of pharmacogenomics drugs that enter the clinic will have a high likelihood of approval. This will change for the better the ecomomics of drug development.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News